Evidence map›Paper›PMID 33088729›Full record

ArticleMethodsX2020

Drug-induced cholestasis assay in primary hepatocytes.

Pieter Van Brantegem, Sagnik Chatterjee, Tom De Bruyn, Pieter Annaert, Neel Deferm

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in MethodsX, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. In Vitro Liver Toxicity Testing of Chemicals: A Pragmatic Approach.International journal of molecular sciences · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Pieter Van BrantegemKU Leuven Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium.
Sagnik ChatterjeePharmaceutical Candidate Optimization, Biocon, Bristol-Myers Squibb R& D Center (BBRC), Syngene International Ltd., Bangalore, India.
Tom De BruynDepartment of Drug Metabolism and Pharmacokinetics, Genentech Inc, South San Francisco, CA, USA.
Pieter AnnaertKU Leuven Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium.
Neel DefermKU Leuven Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium.
KU Leuven · BEBristol-Myers Squibb (India) · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug-induced cholestasis (DIC) is a major cause of clinical failure of drug candidates. Numerous patients worldwide are affected when exposed to marketed drugs exhibiting a DIC signature. Prospective identification of DIC during early compound development remains challenging. Here we describe the optimized

Indexed as

Drug candidate selectionDrug-induced cholestasisDrug-induced liver injuryDrug safety evaluationIn vitro toxicityPrimary hepatocytes

Identifiers

PMID33088729
PMCPMC7559231
OpenAlexW3088938643

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.